• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Study refutes 'conventional' dose griseofulvin in tinea capitis Tx

Article

Lubbock, Texas - Results of a retrospective study evaluating recurrence rates following successful griseofulvin treatment for tinea capitis confirm what most dermatologists knew from their clinical experience - that the dose of griseofulvin used to treat this fungal infection should be at least 20 mg/kg/day.

Related Videos
Related Content
A Novel Approach to Distinguishing Scabies From Atopic Dermatitis

A Novel Approach to Distinguishing Scabies From Atopic Dermatitis

Article
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast
In Interim Analysis, Mogamulizumab Demonstrates Improvements In Mycosis Fungoides, Sézary Syndrome

In Interim Analysis, Mogamulizumab Demonstrates Improvements In Mycosis Fungoides, Sézary Syndrome

Article
ReV Up Your Vitiligo Treatment Strategies

ReV Up Your Vitiligo Treatment Strategies

Podcast
New AAD Atopic Dermatitis Guidelines and Dupilumab Label Updates

New AAD Atopic Dermatitis Guidelines and Dupilumab Label Updates

Article
Reviewing the Rosacea Pipeline: A Look at the Last 10 Years

Reviewing the Rosacea Pipeline: A Look at the Last 10 Years

Article
© 2024 MJH Life Sciences

All rights reserved.